BeyondSpring, Inc. · NASDAQ:BYSI

BeyondSpring — Investor Presentation (April 2024)

35 slides from BeyondSpring's investor presentation, Apr 9, 2024

  1. Slide 1: BeyondSpring Corporate Presentation April 2024

    April 2024| NASDAQ: BYSI

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal

  3. Slide 3: Investment Highlights

    Investment Highlights Plinabulin: Safety Lead Asset Plinabulin: >700 cancer patients treated with good & Efficacy tolerability; Positive Phase 3 data in 2 indications Plinabulin Plinabulin: Dual Benefit in anti-cancer and prevention of CIN; Potential Potential in re-sensitizing in PD-1/PD-L1 progres

  4. Slide 4: Pipeline

    Pipeline Indication/Target Program Preclinical Phase 1 Phase 2 Phase 3 Registration Trial Name / Collaborator NSCLC Plinabulin + Docetaxel DUBLIN-3 (2nd/3rd line) Late stage Plinabulin + PROTECTIVE-1 CIN Prevention Pegfilgrastim & PROTECTIVE-2 SCLC Plinabulin + PD-1 + (2nd/3rd line) CTLA-4 NSCLC (2n

  5. Slide 5: SEED Therapeutics: Target Protein Degradation (TPD 2.0) Company

    SEED Therapeutics: Target Protein Degradation (TPD 2.0) Company TPD Targets 80% of Disease-Causing Proteins That are Currently Undruggable 5

  6. Slide 6: Targeted Protein Degradation Addresses 80% of Disease-Causing Proteins

    Targeted Protein Degradation (TPD) Addresses 80% of Disease- Causing Proteins That are were Undruggable TPD for Undruggable Proteins Druggable Proteins Sriram et al., Molecular Pharmacology, 2018 6

  7. Slide 7: TPD Development History and Recent Renaissance

    TPD Development History and Recent Renaissance SEED Co-founders played pivotal roles in the TPD Process advancement of TPD field • 1996: Dr. Michele Pagano (SEED co-founder) discovered cell cycle regulation by TPD, including E3 ligases; published in Science • 1999: Dr. Lan Huang (SEED co-founder and

  8. Slide 8: World Class Leadership Team and Exceptional Insights in TPD Drug Development

    World Class Leadership Team and Exceptional Insights in TPD Drug Development Lan Huang, PhD + * Avram Hershko MD, PhD+ Ning Zheng, PhD+ Michele Pagano, MD + (Chairman & CEO) “Godfather” of TPD; Howard Hughes Professor, University of Howard Hughes Professor, NYU E3 structural expert; Serial biotech 2

  9. Slide 9: Exceeding Seed Financing Expectations

    Exceeding Seed Financing Expectations SEED Internal Program Milestones Translation of SEED Platforms into Drug Development of SEED’s unique TPD platforms and filed Infrastructure and Organization Pipeline of 8 disclosed programs in patents Building various disease areas • Multi-dimensional platforms

  10. Slide 10: SEED's Differentiation: Multi-dimensional Platforms for E3 Selection

    SEED’s Differentiation: Multi-dimensional Platforms for E3 Selection Knowledge-based Direct Binding Validation LumID: Identify the right E3 in the Quasi Degron Approach “living cell” near protein of interest B B E3 B Target Neo Target Neo Target 1 Quasi Degron B Weakened Binding I L I L E3 C A A E3

  11. Slide 11: Drug R&D Pipeline in Multiple Disease Areas

    8 Drug R&D Pipeline in Multiple Disease Areas Target Molecular IND Indication Target Protein E3 Ligase ID Lead ID IND Filing Selection Glue HTS Candidate 2025 RBM39 FHD KRAS-G12D Oncology Target Beta FEN1 Target Alpha Neurodegeration Tau Immunology Target Gamma Antiviral HBx * SEED owns global IP on

  12. Slide 12: Our RBM39 Degrader Class: Potentially Best-in-Class and First-to-Market

    Our RBM39 Degrader Class: Potentially Best-in-Class and First-to-Market Program Summary • POI: RNA splicing factor RMB39; E3: DCAF15; MOA: RMB39 degrader MG • Target indications: Biomarker selected colon cancer, prostate cancer, neuroblastoma, and others • Development stage: IND candidate; YE2024 IN

  13. Slide 13: TPD: a High Value and Novel Therapeutic Modality

    TPD: a High Value and Novel Therapeutic Modality All top 20 global pharma have TPD programs internally and / or through collaboration Allosteric effect based Covalent binder • Not MG selective Target-Centric • Discovery stage TPD assets has been commanding $35 - $60 libraries • Lack of evidence for

  14. Slide 14: Summary: First to Market and Best in Class

    Summary: First to Market and Best in Class Scalable Business TPD has potential to target 80% of undruggable disease-causing Model proteins. > 600 E3 ligases to be used for multiple disease areas. Target-Centric Identify the right E3 for POI to increase the success rate in drug Differentiation discov

  15. Slide 15: Plinabulin: First-in-class Late Stage Clinical Asset for Cancer Treatment

    Plinabulin: First-in-class Late Stage Clinical Asset for Cancer Treatment 15

  16. Slide 16: First-in-class Asset: Plinabulin

    First-in-class Asset: Plinabulin • Positive Phase 3 study in 2L/3L NSCLC, successfully demonstrated significant Advanced Clinical OS benefit, doubling 2-year, 3-year OS rate – proving plinabulin’s clinical Stage Agent utility • Promising efficacy data in combination with PD-(L)1 and radiation, in IO

  17. Slide 17: Plinabulin is a Differentiated First-in-Class Tubulin Binder

    Plinabulin is a Differentiated First-in-Class Tubulin Binder with a Uniquely Favorable Safety Profile Plinabulin is a reversible tubulin binder and does not change tubulin dynamics Conventional tubulin binding agents (such as taxanes, vinca alkaloids, and colchicine) alter tubulin dynamics upon bind

  18. Slide 18: Plinabulin: Induce Innate and Adaptive Immunity

    Plinabulin: Induce Innate and Adaptive Immunity By depolymerizing microtubules, plinabulin releases, or activates, immune-defense protein GEF-H1. This leads to dendritic cell maturation (the most potent APC). In WT DC cells, plinabulin can induce DC maturation, but not in GEF-H1 deleted DC cells2 Pl

  19. Slide 19: Plinabulin's Immunomodulation and Neutropenia-Mitigating Activities

    Plinabulin’s Immunomodulation and Neutropenia-Mitigating Activities Position it as a Valuable Partner for Immuno-Chemotherapy Combination Regimens These aspects result in an optimal scenario of added efficacy with potentially reduced toxicity. Dendritic Cells M1-like Macrophages Improves Safety* Pli

  20. Slide 20: Plinabulin improves overall survival and enhances safety in 2L/3L NSCLC (Dublin-3 Study)

    Plinabulin improves overall survival and enhances safety in 2L/3L NSCLC (Dublin-3 Study) 20

  21. Slide 21: The EGFR-wild Type 2L/3L NSCLC Have Been a Historically Difficult Space

    The EGFR-wild Type 2L/3L NSCLC Have Been a Historically Difficult Space in Which to Develop Treatment options in Attempts to address treatment 2L/3L NSCLC are limited needs have been challenging Docetaxel-based therapies are the mainstay therapy in 2L/3L Since Nivolumab’s approval 8 years ago, NSCLC

  22. Slide 22: Plinabulin Evaluated in Combination with Docetaxel in a Phase 3 Study

    Plinabulin Has Been Evaluated in Combination with Docetaxel in a Phase 3 Study with advanced, Pre-treated NSCLC Patients Docetaxel + Plinabulin vs. Docetaxel + Placebo in Patients with EGFR Wild-Type NSCLC Study Plan Primary endpoint Secondary endpoints • Global, randomized, single-blinded (patients

  23. Slide 23: Plinabulin + Docetaxel Met its Primary Endpoint (OS)

    Plinabulin + Docetaxel Met its Primary Endpoint (OS) and Showed Significant Improvement in Long-term OS Rate Docetaxel + Docetaxel + placebo Plinabulin Survival Probability (%) OS HR=0.82 mOS benefit 1.1 M Log rank p=0.0399 Log-rank p=0.0399 Months Subjects at Risk Docetaxel (75mg/m2) + placebo 281

  24. Slide 24: Plinabulin Slows Progression and Increased Tolerability of Docetaxel

    Plinabulin Not Only Slows Progressive disease, but Also Increased the Tolerability of Docetaxel and Increased Duration of Treatment Use of plinabulin significantly …allowing more patients to remain on reduced Grade 4 neutropenia docetaxel for a longer duration Grade 4 neutropenia, All Cycles Day 8 %

  25. Slide 25: Plinabulin Successfully Improved Efficacy of SOC in 2L/3L NSCLC

    Plinabulin Successfully Improved Efficacy of SOC in 2L/3L NSCLC, Proving its Clinical Utility, Despite Historical Failures in this Space The addition of plinabulin as a single agent added to 2L/3L NSCLC standard-of- care led to improved overall survival and enhanced safety Efficacy Safety and tolera

  26. Slide 26: Encouraging RT+PD-1+Plinabulin clinical data demonstrates partnering potential

    Encouraging RT+PD-1+Plinabulin clinical data demonstrates Plinabulin’s partnering potential with IO agents RT: Radiation therapy 26

  27. Slide 27: Plinabulin Enhances the Cancer Immunity Cycle with Radiation and Anti-PD1

    Plinabulin Enhances the Cancer Immunity Cycle When Used with Radiation and Anti-PD1 ② Plinabulin 2 Improved antigen presentation ③ Checkpoint Inhibitors Stimulate maturation of dendritic cells to increase antigen presentation. 3 Anti-tumor T cell activation Optimize T cell response 1 ① Radiation/Che

  28. Slide 28: Plinabulin Evaluated in Multiple Immunotherapy Combination Trials

    Plinabulin is Being Evaluated in Multiple Immunotherapy Combination Trials in Collaboration with Major Pharmaceutical Companies Indication/Target Program Preclinical Phase 1 Phase 2 Phase 3 Trial Name / Collaborator ES-SCLC Plinabulin + PD-1 + (1st line) Etoposide / Platinum Investigator Initiated T

  29. Slide 29: RT+anti-PD1+Plinabulin Triple Combination POC in Animals

    RT+anti-PD1+Plinabulin Triple Combination POC in Animals Provides Evidence of Plinabulin’s Immunomodulatory activity Tumor reduction is most robust DC activation is most dramatic in triple I/O combination in triple I/O combination Plinabulin+ RT+PD-1 increased DC maturation T cell doubles in triple

  30. Slide 30: Clinical PoC in Efficacy: Plinabulin Triple Combo Produces Responses

    Clinical PoC in Efficacy: Plinabulin Triple Combo Produces Clinically Meaningful Responses in the Non-Irradiated Tumor Across Multiple Cancers after IO-failure Plinabulin triple combination led to 70% DCR Systemic abscopal effect seen comparing baseline and C3D1 (3 PR, 4 SD) in 10 IO-failed patients

  31. Slide 31: Clinical PoC in MOA: Early Immune Activation in Responding Patients

    Clinical PoC in MOA: Plinabulin-Responding Patients Show Early Immune Activation Evidenced by DC Maturation and Proinflammatory Monocytes in the Peripheral Blood In different cancers, DC maturation and anti-tumor inflammatory macrophages were observed in plinabulin-responding patients Proinflammator

  32. Slide 32: Plinabulin as Potential Add-on Therapy to Current I/O Regimens

    Plinabulin as Potential Add-on Therapy to Current I/O Regimens to Address Severe Unmet Medical Needs PD-1/PD-L1 Inhibitors Potential to greatly expand the - >$30B global annual sales addressable market Current Severe Unmet Medical Needs Plinabulin Clinical Development 2L/3L: PD-1/PD-L1 relapsed/refr

  33. Slide 33: Plinabulin's Multiple MoAs, Proven Clinical Activity, and Strong Patent Protection

    Plinabulin’s Multiple MoAs, Proven Clinical Activity, and Strong Global Patent Protection are Highly Favorable for Partnerships with Immunotherapy Agents…and Beyond Lead Asset Plinabulin Proven clinical efficacy and Enhances the Strong global patent displays dual IO MOAs safety Cancer-Immunity cycle

  34. Slide 34: Investment Highlights

    Investment Highlights Plinabulin: Safety Lead Asset Plinabulin: >700 cancer patients treated with good & Efficacy tolerability; Positive Phase 3 data in 2 indications Plinabulin Plinabulin: Dual Benefit in anti-cancer and prevention of CIN; Potential Potential in re-sensitizing in PD-1/PD-L1 progres

  35. Slide 35: www.beyondspringpharma.com

    www.beyondspringpharma.com 35

BeyondSpring — Investor Presentation (April 2024) on 6ix